切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2018, Vol. 07 ›› Issue (01) : 82 -86. doi: 10.3877/cma.j.issn.2095-3232.2018.01.020

所属专题： 文献；

基础研究

miR-548j-5p表达对胰腺癌侵袭能力的影响
何睿智1, 彭丰1, 冯业晨1, 郭兴军1, 李旭1, 王敏1, 田锐1, 朱峰1, 秦仁义1,†()   
  1. 1. 430030　武汉，华中科技大学同济医学院附属同济医院胆胰外科
  • 收稿日期:2017-11-06 出版日期:2018-02-10
  • 通信作者: 秦仁义
  • 基金资助:
    国家自然科学基金(81502633，81272659)

Effect of miR-548j-5p expression on invasion of pancreatic cancer

Ruizhi He1, Feng Peng1, Yechen Feng1, Xingjun Guo1, Xu Li1, Min Wang1, Rui Tian1, Feng Zhu1, Renyi Qin1,†()   

  1. 1. Department of Biliary and Pancreatic Surgery, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan 430030, China
  • Received:2017-11-06 Published:2018-02-10
  • Corresponding author: Renyi Qin
  • About author:
    Corresponding author: Qin Renyi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

何睿智, 彭丰, 冯业晨, 郭兴军, 李旭, 王敏, 田锐, 朱峰, 秦仁义. miR-548j-5p表达对胰腺癌侵袭能力的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2018, 07(01): 82-86.

Ruizhi He, Feng Peng, Yechen Feng, Xingjun Guo, Xu Li, Min Wang, Rui Tian, Feng Zhu, Renyi Qin. Effect of miR-548j-5p expression on invasion of pancreatic cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(01): 82-86.

目的

探讨miR-548j-5p在胰腺癌中的表达及其对胰腺癌侵袭能力的影响。

方法

本研究组织标本来源于2016年1月至2017年1月在华中科技大学同济医学院附属同济医院接受诊治的16例胰腺癌患者。其中男8例，女8例；年龄41～62岁，≤50岁7例，>50岁9例。患者均签署知情同意书，符合医学伦理学规定。采用RT-PCR检测胰腺癌及癌旁组织中miR-548j-5p的表达量。采用miR-548j-5p的mimic、inhibitor分别转染胰腺癌PANC-1细胞，构建过表达、低表达miR-548j-5p的PANC-1细胞，其对应的空载体Ctrl转染胰腺癌PANC-1细胞作为对照组。Transwell实验检测miR-548j-5p对PANC-1细胞侵袭能力的影响，划痕实验检测miR-548j-5p对PANC-1细胞迁移能力的影响。3组比较采用单因素方差分析和LSD-t检验。

结果

胰腺癌中miR-548j-5p相对表达量中位数为0.35（0.03～4.47），明显低于癌旁组织的4.30（0.04～65.55） （Z=-2.689，P<0.05）。Transwell实验结果显示miR-548j-5p过表达组的平均穿膜细胞数为（58±34）个，明显少于对照组的（231±61）个（LSD-t=-2.852，P<0.05）；miR-548j-5p低表达组穿膜细胞数为（491±149）个，明显多于对照组（LSD-t=4.313，P<0.05）。划痕实验结果显示miR-548j-5p过表达组划痕融合率为（20±8）%，明显低于对照组的（38±6）%（LSD-t=-3.759，P<0.05）；miR-548j-5p低表达组划痕融合率为（53±6）%，明显高于对照组的（38±6）%（LSD-t=2.946，P<0.05）。

结论

miR-548j-5p在胰腺癌中低表达，miR-548j-5p过表达能降低胰腺癌侵袭转移能力。

关键词: 微RNAS, 胰腺肿瘤, 肿瘤侵润, 肿瘤转移, 548j-5p基因
Objective

To explore the expression of miR-548j-5p in pancreatic cancer and its effect on the invasion of pancreatic cancer.

Methods

Tissue samples of 16 patients with pancreatic cancer who received treatment in Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology between January 2016 and January 2017 were collected. There were 8 males and 8 females, aged from 41 to 62, including 7 cases with an age of ≤50 and 9 cases with an age of >50. The informed consents of all patients were obtained and the local ethical committee approval was received. The expression of miR-548j-5p in pancreatic cancer and adjacent tissues was detected by RT-PCR. PANC-1 cells were transfected by mimic and inhibitor of miR-548j-5p to construct PANC-1 cells with over-expression and low-expression of miR-548j-5p. And in control group, PANC-1 cells were transfected with empty plasmid Ctrl. The effect of miR-548j-5p on PANC-1 invasion was detected by Transwell assay, and its effect on PANC-1 metastasis was evaluated by wound scratch assay. Comparison of three groups was conducted by one-way analysis of variance and LSD-t test.

Results

The median relative expression of miR-548j-5p in pancreatic cancer was 0.35(0.03-4.47), significantly lower than 4.30 (0.04-65.55) in adjacent tissues (Z=-2.689, P<0.05). Transwell assay results showed that the average number of cells penetrating membrane was (58±34) in miR-548j-5p over-expression group, significantly lower than (231±61) in control group (LSD-t=-2.852, P<0.05); and it was (491±149) in miR-548j-5p low-expression group, significantly higher than that in control group (LSD-t=4.313, P<0.05). The wound scratch assay results showed that the wound scratch healing rate was (20±8)% in miR-548j-5p over-expression group, significantly lower than (38±6)% in control group (LSD-t=-3.759, P<0.05); and it was (53±6)% in miR-548j-5p low-expression group, significantly higher than that in control group (LSD-t=2.946, P<0.05).

Conclusions

Low expression of miR-548j-5p is observed in pancreatic cancer. Over expression of miR-548j-5p can decrease the invasive and metastatic ability of pancreatic cancer.

Key words: MicroRNAs, Pancreatic neoplasms, Neoplasm invasiveness, Neoplasm metastasis, 548j-5p gene
图1 miR-548j-5p在胰腺癌组织中的表达情况
图2 Transwell法检测胰腺癌细胞侵袭能力
图3 细胞划痕实验检测胰腺癌细胞的迁移能力
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2]
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 155(6):977-988.
[3]
Genovese G, Carugo A, Tepper J, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer[J]. Nature, 2017, 542(7641):362-366.
[4]
Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy[J]. Expert Opin Ther Targets, 2016, 20(3):341-359.
[5]
Adams BD, Parsons C, Walker L, et al. Targeting noncoding RNAs in disease[J]. J Clin Invest, 2017, 127(3):761-771.
[6]
Yonemori K, Kurahara H, Maemura K, et al. MicroRNA in pancreatic cancer[J]. J Hum Genet, 2017, 62(1):33-40.
[7]
Huang J, Liu J, Chen-Xiao K, et al. Advance in microRNA asa potential biomarker for early detection of pancreatic cancer[J]. Biomark Res, 2016(4):20.
[8]
Merhautova J, Demlova R, Slaby O. MicroRNA-based therapy in animal models of selected gastrointestinal cancers[J]. Front Pharmacol, 2016(7):329.
[9]
Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker[J]. Clin Cancer Res, 2017, 23(1):116-123.
[10]
Zoghbi HY, Beaudet AL. Epigenetics and human disease[J]. Cold Spring Harb Perspect Biol, 2016, 8(2):a019497
[11]
Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy[J]. Cancer Treat Rev, 2017(55):200-208.
[12]
Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond[J]. Pharmacol Ther, 2017(173):118-134.
[13]
van Kampen JG, Marijnissen-van Zanten MA, Simmer F, et al. Epigenetic targeting in pancreatic cancer[J]. Cancer Treat Rev, 2014, 40(5):656-664.
[14]
Frampton AE, Castellano L, Colombo T, et al. Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression[J]. Lancet, 2015, 385 Suppl 1:S37.
[15]
Wang C, Liu P, Wu H, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3[J]. Oncotarget, 2016, 7(12):14912-14924.
[16]
Botla SK, Savant S, Jandaghi P, et al. Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression[J]. Cancer Res, 2016, 76(14):4149-4159.
[17]
Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements[J]. PLoS One, 2007, 2(2):e203.
[18]
Shi Y, Qiu M, Wu Y, et al. MiR-548-3p functions as an anti-oncogenic regulator in breast cancer[J]. Biomed Pharmacother, 2015(75):111-116.
[19]
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222.
[20]
Li Y, Xie J, Xu X, et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1[J]. Protein Cell, 2013, 4(2):130-141.
[21]
Zhan Y, Liang X, Li L, et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1[J]. Mol Oncol, 2016, 10(6):838-849.
[1] 罗文斌, 韩玮. 胰腺癌患者首次化疗后中重度骨髓抑制的相关危险因素分析及预测模型构建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 357-362.
[2] 马中正, 杨云川, 马翔, 周迟, 丁丁, 霍俊一, 徐楠, 崔培元, 周磊. 胰腺癌双硫死亡相关的lncRNA预后模型的构建及免疫反应研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 368-376.
[3] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[4] 史成宇, 季晓琳, 田莉莹, 张来香. 腹腔镜胰十二指肠切除术中第14c/d组淋巴结清扫在胰头癌中的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 430-433.
[5] 朱江, 张进, 孔云飞, 李军, 宋旭. 核梭杆菌和胰腺癌的关系及临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 448-451.
[6] 魏孔源, 仵正, 王铮, 黎韡. 机器人胰腺中段切除后远端胰腺消化道不同重建方式初探[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 295-300.
[7] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[8] 郭诗翔, 谭明达, 王槐志. 胰头癌淋巴结清扫再思考[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 625-628.
[9] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[10] 周倜, 吴嘉, 韩方, 徐林伟, 张宇华. 新辅助治疗时代胰腺癌淋巴结清扫研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 634-639.
[11] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[12] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[13] 罗柳平, 吴萌萌, 陈欣磊, 林科灿. 胰腺全系膜切除在胰头癌根治术中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 651-656.
[14] 张瑜, 姜梦妮. 基于DWI信号值构建局部进展期胰腺癌放化疗生存获益预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 657-664.
[15] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号